CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India

Environmental Toxicology and Pharmacology

Volumn 29, Issue 2, 2010, Pages 126-130

  Kumar, Vivek ^a   Singh, Satyender ^b   Yadav, Chandra Shekhar ^a   Ahmed, Rafat Sultana ^a   Gupta, Sanjay ^a   Pasha, Syed Tazeen ^c   Tripathi, Ashok Kumar ^a   Banerjee, Basu Dev ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF COMMUNICABLE DISEASES   (India)

^c GOVERNMENT OF INDIA   (India)

Author keywords

Cancer; Cytochrome P450; Polymorphism; Smoking

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 1B; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIA; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL;

EID: 77951622025     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2009.12.001     Document Type: Article

References (44)

1. Ada A.O., Süzen S.H., Iscan M. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase M1 and T1 in Turkish population. Toxicol. Lett. 2004, 151:311-315.
2. Ambrosone C.B., Freudenheim J.L., Graham S., Marshall J.R., Vena J.E., Brasure J.R., Laughlin R., Nemoto T., Michalek A.M., Harrington A., Ford T.D., Shields P.G. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 1995, 55:3483-3485.
3. Anantharaman D., Chaubal P.M., Kannan S., Bhisey R.A., Mahimkar M.B. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis 2007, 28:1455-1462.
4. Badawi A.F., Cavalieri E.L., Rogan E.G. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16-hydroxylation of estradiol. Metabolism 2001, 50:1001-1003.
5. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 2000, 9:3-28.
6. Buch S., Kotekar A., Kawle D., Bishey R. Polymorphism at CYP and GST gene loci. Prevalence in Indian population. Eur. J. Clin. Pharmacol. 2001, 57:553-555.
7. Cascorbi I., Brockmoller J., Roots I. C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages and impact on lung cancer susceptibility. Cancer Res. 1996, 56:4965-4969.
8. Cosma G., Crofts F., Taioli E., Toniolo P., Garte S.J. The relationship between genotype and function of the human CYPlAl gene. Toxicol. Environ. Health 1993, 40:315-322.
9. Crofts F., Cosma G.N., Currie D., Taioli E., Toniolo P., Garte S.J. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 1993, 14:1729-1731.
10. Crofts F., Taioll E., Trachman J., Cosma G.N., Currie D., Toniolo P., Garte S.J. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994, 15:2961-2963.
11. Doll R. Uncovering the risk of smoking: historical perspective. Stat. Meth. Med. Res. 1998, 7:87-117.
12. Garte S.J. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998, 19:1329-1332.
13. Garte S.J., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L. Metabolic gene polymorphism frequencies in control population. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1239-1248.
14. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1999, 39:1-17.
15. Guengerich F.P. Cytochromes P450, drugs, and diseases. Mol. Interv. 2003, 3:194-204.
16. Gonzalez F.J. Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 1990, 45:1-38.
17. Gonzalez F.J. Role of gene knockout and transgenic mice in the study xenobiotic metabolism. Drug Metab. Rev. 2003, 35:319-335.
18. Hayashi S.I., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung-cancer- associated Mspl polymorphism with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J. Biochem. 1991, 110:407-411.
19. Katoh T., Inatomi H., Nagaoka A., Sugita A. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis (London) 1995, 16:655-657.
20. Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of cytochrome P4501A1 gene. FEBS Lett. 1990, 263:131-133.
21. Keshava C., Canlies E.C., Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am. J. Epidemiol. 2004, 160:825-841.
22. Kumar V., Singh S., Ahmed R.S., Banerjee B.D., Ahmed T., Pasha S.T. Frequency of common CYP1B1 polymorphic variations in Delhi population of Northern India. Environ. Toxicol. Pharmacol. 2009, 28:392-396.
23. Le Marchand L., Sivaraman L., Pierce L., Seifried A., Lum A., Wilkens L.R., Lau A.F. Association of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 1998, 58:4858-4863.
24. Majumder P.P., Mukherjee B.N. Genetic diversity and affinities among Indian populations; an overview. Human Population Genetics 1993, 255-275. Plenum Press, New York. P.P. Majumder (Ed.).
25. Meyer U.A. Pharmacogentics. The slow, the rapid and the ultrarapid. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:1983-1984.
26. Miller, B.A., Kolonel, L.N., Bernstein, L., Young, J.L., Swanson, Jr., G.M., West, D., Key, C.R., Liff, J.M., Glover, C.S., Alexander, G.A., 1996. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. Natl. Cancer Inst., NIH Publ. No. 96-4104, Bethesda, MD.
27. Morita S., Yano M., Shiozaki H., Tsujinaka T., Ebisui C., Morimoto T., Kishibuti M., Fujita J., Ogawa A., Taniguchi M., Inoue M., Tamura S., Yamazaki K., Kikkawa N., Mizunoya S., Monden M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous cell carcinoma of the esophagus. Int. J. Cancer 1997, 71:192-195.
28. Morita S., Yano M., Tsujinaka T., Akiyama Y., Taniguchi M., Kaneko K., Miki H., Fujii T., Yoshino K., Kusuoka H., Monden M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and neck squamous-cell carcinoma. Int. J. Cancer 1999, 80:685-688.
29. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360:1155-1162.
30. Nimura Y., Yokoyama S., Fujimori M., Aoki T., Adachi W., Nasu T., He M., Ping Y.M., Iida F. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer (Phila.) 1997, 80:852-857.
31. Paris P.L., Kupelian P.A., Hall J.M., Williams T.L., Levin H., Klein E.A., Casey G., Witte J.S. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 1999, 8:901-905.
32. Rais N., Chawla Y.K., Kohli K.K. CYP3A phenotypes and genotypes in North Indians. Eur. J. Clin. Pharmacol. 2006, 62:417-422.
33. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. (Bethesda) 1998, 90:1225-1229.
34. Roland J., Breton L. Atlas of the Languages and Ethnic Communities of South Asia 1993, Saga publication, New Delhi, pp. 21-39.
35. Singh S., Kumar V., Thakur S., Banerjee B.D., Grover S.S., Rawat D.S., Pasha S.T., Jain S.K., Lal S., Rai A. Genetic polymorphism of glutathione S-transferase M1 and T1 in Delhi population of Northern India. Environ. Toxicol. Pharmacol. 2009, 28:25-29.
36. Sobti R.C., Sharma S., Joshi A., Jindal S.K., Janmeja A. Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a North Indian population. Mol. Cell Biochem. 2004, 266:1-9.
37. Song N., Tan W., Xing D., Lin D. CYP1A1 polymorphism and risk to lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 2001, 22:11-16.
38. Sreeja L., Syamala V., Hariharan S., Madhavan J., Devan S.C., Ankathil R. Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J. Hum. Genet. 2005, 50:618-627.
39. Srivastava D.S., Mandhani A., Mittal R.D. Genetic polymorphisms of cytochrome P450 CYP1A1 (2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India. Arch. Toxicol. 2008, 82:633-639.
40. Tanimoto K., Hayashi S., Yoshiga K., Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol. 1999, 35:191-196.
41. vanSchaik R.H.N., deWildt S.N., vanIperen N.M., Uitterlinden A.G., vandenAnker J.N., Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin. Chem. 2000, 46:1834-1835.
42. Vineis, P., Lang, M., Caporaso, N., Cuzick, J., Boffetta, P., (Eds.), 1998. Metabolic Polymorphisms and Cancer. IARC, Lyon.
43. Walker A.H., Jaffe J.M., Gunasegaram S., Cummings S.A., Huang C.S., Chern H.D., Olopade O.I., Weber B.L., Rebbeck T.R. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum. Mutat. 1998, 12:289.
44. Yang Q., Khoury M.J., Friedman J.M., Little J., Flanders W.D. How many genes under lie the occurrence of common complex diseases in the population?. Int. J. Epidemiol. 2005, 34:1129-1137.